This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Generation of a chemical genetic model for JAK3
Scientific Reports Open Access 12 May 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Garber, K. Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market. Nat Biotechnol 31, 3–4 (2013). https://doi.org/10.1038/nbt0113-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0113-3
This article is cited by
-
Generation of a chemical genetic model for JAK3
Scientific Reports (2021)
-
New partner for Galapagos JAK drug
Nature Biotechnology (2016)
-
Setback for JAK2 inhibitors
Nature Biotechnology (2014)